Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2026-04-22 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于向银行申请授信额度的公告
Capital/Financing Update Classification · 86% confidence The document is an official announcement by Shanghai Medicilon Biopharma (证券代码：688202) regarding the board resolution to apply for a bank credit facility of up to RMB 1.2 billion for corporate financing needs. It details proposed credit lines, types of loans, authorization of management to execute financing documents, and subsequent shareholder approval. This is clearly an update on the company’s financing activities and credit arrangements rather than a report publication or regulatory filing of another type. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2026-04-22 Chinese
美迪西：关于召开2025年年度股东会的通知
Proxy Solicitation & Information Statement Classification · 86% confidence The document is the official notice of the 2025 Annual Shareholders’ Meeting, detailing the meeting date, venue, agenda items, voting procedures, and includes the authorization (proxy) form for shareholders to appoint representatives and cast votes. This matches the definition of a Proxy Solicitation & Information Statement (materials sent to shareholders to provide information and request votes for meetings).
2026-04-22 Chinese
美迪西：2025年度独立董事述职报告（许金叶-已届满离任）
Regulatory Filings Classification · 70% confidence The document is the “2025年度独立董事述职报告” by an independent director, detailing her background, meeting attendance, key oversight activities, and overall evaluation. It is neither an earnings release, financial report, proxy statement, nor any other specific filing in our taxonomy. It is a required regulatory disclosure by the company but does not fit into the defined specific categories. Therefore, it should be classified under the fallback category “Regulatory Filings (RNS).”
2026-04-22 Chinese
美迪西：关于续聘公司2026年度审计机构及内控审计机构的公告
Regulatory Filings Classification · 62% confidence The document is a corporate announcement informing shareholders and the market of the board’s resolution to reappoint the external audit firm and internal control auditor for the 2026 fiscal year. It does not contain an actual audit report or financial statements, nor is it a proxy statement or detailed investor presentation. It is a routine regulatory announcement about auditor appointment, so it best fits the general Regulatory Filings category (RNS).
2026-04-22 Chinese
美迪西：关于2025年度计提资产减值准备的公告
Regulatory Filings Classification · 40% confidence The document is an announcement by Shanghai Medici of its 2025 asset impairment provisions. It sets out accounting estimates, audit committee and board opinions, and the impact on profits. It is not a full annual or interim report, not an earnings release, not an AGM publication, nor a proxy or share issue notice. It is a standalone regulatory disclosure of an accounting event, fitting best into the general Regulatory Filings category (RNS).
2026-04-22 Chinese
美迪西：关于开展外汇套期保值业务的公告
Regulatory Filings Classification · 87% confidence The document is a formal stock exchange announcement by Shanghai Medixi Biopharma’s board regarding the authorization and details of a foreign exchange hedging business (目的、额度、对手方、风险管理、会计处理等). It is not a full financial report (10-K or IR), not a dividend notice, fundraising or capital change (CAP or SHA), nor a management change (MANG) or earnings release (ER). It is a regulatory announcement of an operational business decision filed with the exchange, fitting the fallback category “Regulatory Filings” (RNS).
2026-04-22 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.